JP4918502B2 - 薬剤耐性菌による感染性病状のための非経口的併用療法 - Google Patents

薬剤耐性菌による感染性病状のための非経口的併用療法 Download PDF

Info

Publication number
JP4918502B2
JP4918502B2 JP2007554741A JP2007554741A JP4918502B2 JP 4918502 B2 JP4918502 B2 JP 4918502B2 JP 2007554741 A JP2007554741 A JP 2007554741A JP 2007554741 A JP2007554741 A JP 2007554741A JP 4918502 B2 JP4918502 B2 JP 4918502B2
Authority
JP
Japan
Prior art keywords
present
vancomycin
ceftriaxone
pharmaceutical composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007554741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008530082A5 (enExample
JP2008530082A (ja
Inventor
チャウダリ，マヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Venus Remedies Ltd
Original Assignee
Venus Remedies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd
Publication of JP2008530082A publication Critical patent/JP2008530082A/ja
Publication of JP2008530082A5 publication Critical patent/JP2008530082A5/ja
Application granted granted Critical
Publication of JP4918502B2 publication Critical patent/JP4918502B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2007554741A 2005-02-14 2006-02-08 薬剤耐性菌による感染性病状のための非経口的併用療法 Expired - Fee Related JP4918502B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN308/DEL/2005 2005-02-14
IN308DE2005 2005-02-14
PCT/IN2006/000044 WO2006085337A1 (en) 2005-02-14 2006-02-08 Parenteral combination therpy for infective conditions with drug resistant bacterium

Publications (3)

Publication Number Publication Date
JP2008530082A JP2008530082A (ja) 2008-08-07
JP2008530082A5 JP2008530082A5 (enExample) 2009-04-02
JP4918502B2 true JP4918502B2 (ja) 2012-04-18

Family

ID=36337659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007554741A Expired - Fee Related JP4918502B2 (ja) 2005-02-14 2006-02-08 薬剤耐性菌による感染性病状のための非経口的併用療法

Country Status (15)

Country Link
US (2) US7960337B2 (enExample)
EP (1) EP1848413B1 (enExample)
JP (1) JP4918502B2 (enExample)
KR (2) KR20070085674A (enExample)
CN (1) CN101080221A (enExample)
AU (1) AU2006213441B2 (enExample)
BR (1) BRPI0607168A2 (enExample)
CA (1) CA2597812C (enExample)
ES (1) ES2482700T3 (enExample)
MX (1) MX2007009754A (enExample)
NZ (1) NZ555077A (enExample)
PT (1) PT1848413E (enExample)
UA (1) UA91208C2 (enExample)
WO (1) WO2006085337A1 (enExample)
ZA (1) ZA200704393B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080227732A1 (en) * 2005-05-13 2008-09-18 Venus Remedies Limited Treatment and Control of Severe Infections Including Cystic Fibrosis
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
GB2459126A (en) * 2008-04-10 2009-10-14 Peter Wilson Antimicrobial agent
CA2768582C (en) * 2009-07-24 2017-02-14 University Of Tennessee Research Foundation Spectinamides as anti-tuberculosis agents
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
JP5913367B2 (ja) 2011-01-05 2016-04-27 ホスピーラ インコーポレイテッド バンコマイシンの噴霧乾燥
ITLO20110001A1 (it) * 2011-05-03 2012-11-04 Fisiopharma Srl Flaconi di vancomicina cloroidrata con stabilità migliorata
RU2491921C1 (ru) * 2012-07-11 2013-09-10 Общество с ограниченной ответственностью "Опытно-технологическая фирма "Этрис" Способ лечения мастита у коров в сухостойный период
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
WO2014151845A1 (en) 2013-03-15 2014-09-25 Scuderi Group, Inc. Split-cycle engines with direct injection
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
BE1021242B1 (nl) * 2014-06-11 2015-09-08 Neogen N.V. Teicoplanine lyofilisaten
WO2016071495A1 (en) 2014-11-06 2016-05-12 Xellia Pharmaceuticals Aps Glycopeptide compositions
DK3416669T3 (da) * 2016-02-19 2025-08-18 Klaus Brandenburg Midler og metoder til behandling af bakterielle infektioner
MX388732B (es) 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
CN107661470A (zh) * 2016-08-29 2018-02-06 成都特兰辰亚生物科技有限公司 添加有萘夫西林钠治疗痢疾的组合物
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US11433115B2 (en) 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775533A (en) 1987-02-24 1988-10-04 Erbamont, Inc. Reconstitution of dry fill cyclophosphamide
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
GB9500978D0 (en) 1995-01-19 1995-03-08 Smithkline Beecham Plc Pharmaceutical formulations
AU6698496A (en) 1995-07-17 1997-02-18 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Metal-containing ribonucleotide polypeptides
JP4142149B2 (ja) * 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US7378408B2 (en) 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection

Also Published As

Publication number Publication date
EP1848413B1 (en) 2014-04-09
NZ555077A (en) 2010-03-26
ZA200704393B (en) 2008-09-25
UA91208C2 (ru) 2010-07-12
PT1848413E (pt) 2014-07-18
US8778873B2 (en) 2014-07-15
EP1848413A1 (en) 2007-10-31
ES2482700T3 (es) 2014-08-04
AU2006213441A1 (en) 2006-08-17
WO2006085337B1 (en) 2006-11-02
AU2006213441B2 (en) 2011-12-01
BRPI0607168A2 (pt) 2009-08-11
KR20090052893A (ko) 2009-05-26
CA2597812C (en) 2012-01-24
MX2007009754A (es) 2007-11-07
JP2008530082A (ja) 2008-08-07
US20110257079A1 (en) 2011-10-20
US7960337B2 (en) 2011-06-14
CN101080221A (zh) 2007-11-28
US20080188403A1 (en) 2008-08-07
CA2597812A1 (en) 2006-08-17
WO2006085337A1 (en) 2006-08-17
KR20070085674A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
CA2597812C (en) Parenteral combination therapy for infective conditions with drug resistant bacterium
Kaye et al. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management
Rose et al. Tigecycline: first of a new class of antimicrobial agents
JP6870029B2 (ja) セフトロザン抗生物質組成物
Patil et al. Bactericidal and bacteriostatic
US20100197650A1 (en) Compositions and methods of treatment comprising ceftaroline
Rusu et al. The new fifth-generation cephalosporins–a balance between safety and efficacy
Kaye et al. Multidrug-resistant pathogens: Mechanisms of resistance and epidemiology
Rizzo et al. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use
JP2008540515A (ja) 嚢胞性線維症を含む重症感染症の処置および管理
Fulton et al. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients
Manfredi et al. Novel pharmaceutical molecules against emerging resistant gram-positive cocci
BR112013030282B1 (pt) Composições compreendendo cefepima e tazobactama
Pacifici Clinical pharmacology of tigecycline in children
Gauger et al. Cefetamet in the treatment of acute sinusitis in adult patients
Juneja et al. Staphylococcus Infections and Emerging Drug Resistance: A Global Concern
Friedland et al. New antibiotics
WO2024079094A1 (en) Methods of treating staphylococcus aureus bacteremia infections
Pezzani Cefuroxime
Daveson Cefoxitin, cefotetan, and other cephamycins
Rizvi et al. Ceftobiprole-A novel cephalosporin to combat MRSA
WO2024231522A1 (en) Therapy
Carrasco et al. Microbiological and Pharmacological Principles of Recent Antibiotic Therapy
Rafiei Cephalexin
ab Rahman et al. 25 Cefoperazone and Cefoperazone–Sulbactam

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120124

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120130

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150203

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees